Inari Medical FY2027 EPS Forecast Reduced by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Analysts at Leerink Partnrs reduced their FY2027 earnings per share estimates for shares of Inari Medical in a report released on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.54 per share for the year, down from their previous estimate of $0.56. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2028 earnings at $0.97 EPS.

Other research analysts also recently issued reports about the company. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft initiated coverage on Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Leerink Partners initiated coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price target for the company. Stifel Nicolaus initiated coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target for the company. Finally, Robert W. Baird increased their price target on Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $58.89.

Inari Medical Price Performance

Shares of NARI opened at $50.83 on Tuesday. The company has a market cap of $2.98 billion, a P/E ratio of -37.65 and a beta of 0.96. The stock has a fifty day moving average price of $45.73 and a 200 day moving average price of $47.38. Inari Medical has a 12 month low of $36.73 and a 12 month high of $67.13.

Institutional Investors Weigh In On Inari Medical

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares in the last quarter. KBC Group NV lifted its stake in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares in the last quarter. 90.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now directly owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. This represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock valued at $8,990,990 over the last 90 days. 10.60% of the stock is currently owned by corporate insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.